Lipid Management Connect
Profile Image
  • Saved



Conclusions: SVI varies across the US states and is associated with prevalent cardiovascular comorbidities and ASCVD, independent of age, race and ethnicity, sex, employment, income, and health care coverage. SVI may be a useful assessment tool for health policy makers and health systems researchers examining multilevel influences on...

Profile Image
  • Saved
Pleiotropic Benefits of Statins in Cardiovascular Diseases

Pleiotropic Benefits of Statins in Cardiovascular Diseases

Source : https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1873-1978

Drug Res (Stuttg) DOI: 10.1055/a-1873-1978 1   Department of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India 1   Department of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India 1...



Relevance: This article examines some of the existing molecular explanations underlying statin pleiotropy and discusses if they have clinical relevance in cardiovascular diseases.

Profile Image
  • Saved
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

Source : https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00916-3/fulltext

Among patients with ASCVD, moderate-intensity statin with ezetimibe combination therapy was non-inferior to high-intensity statin monotherapy for the 3-year composite outcomes with a higher proportion of patients with LDL cholesterol...



Interpretation: Among patients with ASCVD, moderate-intensity statin with ezetimibe combination therapy was non-inferior to high-intensity statin monotherapy for the 3-year composite outcomes with a higher proportion of patients with LDL cholesterol concentrations of less than 70 mg/dL and lower intolerance-related drug discontinuation or dose...

Profile Image
  • Saved



Conclusion: In summary, empagliflozin activated Wnt/β-catenin to stimulate FUNDC1-dependent mitochondrial quality surveillance, ultimately improving mitochondrial function and cardiac performance during CRS-3. Thus, empagliflozin could be considered for the clinical management of heart function following acute kidney injury.



Conclusions:...

Profile Image
  • Saved
Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: data mining of the FDA Adverse Event Reporting System - PubMed

Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: data mining of the FDA Adverse Event Reporting System - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35818959/

doi: 10.1111/bcp.15460. Online ahead of print. 1 Research Division of Clinical Pharmacology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. 2 Department of Respiratory, Wuxi No.5 People's...


Conclusion: Data mining of the FAERs is useful for examining PCSK9 inhibitor-induced AEs. Herein, our findings were largely consistent with clinical experience and could help clinicians improve the safety of PCSK9 inhibitors in clinical practice.

Profile Image